Pasithea Reports PAS-004 Phase 1 Data Showing Prolonged Stable Disease

The company said four heavily pre-treated patients remained on PAS-004 for more than 300 days; two continued treatment for over 500 days, including patients with recurrent, metastatic BRAF V600E melanoma.